flapixant (BAY1902607) / Bayer, Evotec - LARVOL DELTA

The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial. (PubMed, Respir Res) - P1/2 | "Filapixant proved to be efficacious, safe, and-apart from the occurrence of taste disturbances, especially at higher dosages-well tolerated during the short therapeutic intervention. Clinical trial registration EudraCT, eudract.ema.europa.eu, 2018-000129-29; ClinicalTrials.gov, NCT03535168."

Journal • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

[VIRTUAL] Safety and efficacy of P2X3 antagonist BAY 1902607 in refractory chronic cough (ERS 2020) - P1/2 | "BAY 1902607 significantly reduced 24-hour cough frequency and severity at doses ≥80 mg. Despite high P2X3 receptor selectivity of BAY 1902607, dose-related AEs of taste disturbance were observed in many patients."

Clinical • JAK3